Skip to main content
PMC home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;95(2):168–175. doi: 10.1111/j.1349-7006.2004.tb03199.x

DE‐310, a novel macromolecular carrier system for the camptothecin analog DX‐8951f: Potent antitumor activities in various murine tumor models

Eiji Kumazawa 1,✉, Yusuke Ochi 1,✉
PMCID: PMC11158227  PMID: 14965368

Abstract

DE‐310 is a novel macromolecular conjugate composed of DX‐8951f, a camptothecin analog, and a carboxymethyldextran polyalcohol carrier, which are covalently linked via a peptidyl spacer. In a murine Meth A (fibrosarcoma) solid tumor model, once daily×5 treatments (qd×5) with DX‐8951f at the maximum tolerated dose (MTD) were required to shrink the tumor, and DX‐8951f (qd×5) at 1/4 MTD was required to inhibit tumor growth. A single treatment (qd×1) with DE‐310 at the MTD or 1/4 MTD shrank the tumor, with no body weight loss occurring at 1/4 MTD. Even at 1/16 MTD, DE‐310 inhibited tumor growth. In a long‐term assay, Meth A solid tumors disappeared in mice treated with DE‐310 (qd×1) at the MTD and 1/2 MTD, and all 6 mice remained tumor‐free on the 60th day after administration. Repeated injection (4 times) on schedules of every 3 days, 7 days or 14 days demonstrated that multiple treatment with DE‐310 produced greater tumor growth delay than a single treatment with DE‐310. Against 5 human tumor (colon and lung cancer) xenografts in mice, DE‐310 (qd×1) was as effective as DX‐8951f administered once every 4 days, 4 times. The life‐prolonging activity of DE‐310 was assessed in lung (3LL, Lewis lung carcinoma) and liver (M5076, histiocytoma) metastasis models. Against 3LL, DE‐310 (qdx1) at the MTD to 1/3 MTD significantly prolonged survival, with an increase in life span (ILS) of 4.8‐ to 1.6‐fold, respectively, over that in untreated control mice. Also, DE‐310 (qd×1) significantly prolonged survival in the liver metastasis model of M5076. These results demonstrate that DE‐310 is a promising agent for the treatment of cancer.

References

  • 1. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA. Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminate. J Am Chem Soc 1966; 83: 3888–90. [Google Scholar]
  • 2. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces proteinlinked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260: 14873–8. [PubMed] [Google Scholar]
  • 3. Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC‐100880): correlation with preclinical studies. Cancer Chemother Rep 1972; 56: 515–21. [PubMed] [Google Scholar]
  • 4. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Phase II study of camptothecin (NSC‐100880) in the treatment of advanced gastroinstinal cancer. Cancer Chemother Rep 1972; 56: 95–101. [PubMed] [Google Scholar]
  • 5. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M. Antitumor activity of 7‐ethyl‐10‐[4‐(1‐piperidino)‐1‐piperidino]carbonyloxycamptothecin, a new novel water‐soluble derivative of camptothecin, against murine tumors. Cancer Res 1987; 47: 5944–7. [PubMed] [Google Scholar]
  • 6. Tsuruo T, Matsuzaki T, Matsushita T, Saito H, Yokokura T. Antitumor effect of CPT‐11, a new derivative of camptothecin, against pleiotropic drug‐resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 1988; 21: 71–4. [DOI] [PubMed] [Google Scholar]
  • 7. Kawato Y, Furuta A, Aonuma M, Yasuoka M, Yokokura T, Matsumoto K. Antitumor activity of a camptothecin derivative, CPT‐11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 1991; 28: 192–8. [DOI] [PubMed] [Google Scholar]
  • 8. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993; 85: 271–91. [DOI] [PubMed] [Google Scholar]
  • 9. Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, Ariyoshi H, Ichimaru M, Sakai Y, Oguro M, Ito Y, Morishima Y, Tokomaku S, Ota K. An early phase II study of CPT‐11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 1990; 8: 1907–12. [DOI] [PubMed] [Google Scholar]
  • 10. Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K, Fujiwara Y, Liu LF, Saijo N. Establishment of a camptothecin analogue (CPT‐11)‐resistant cell line of human non‐small cell lung cancer: characterization and mechanism of resistance. Cancer Res 1990; 50: 5919–24. [PubMed] [Google Scholar]
  • 11. Kawato Y, Terasawa H. Recent advances in the medicinal chemistry and pharmacology of camptothecin. Prog Med Chem 1997; 34: 69–109. [Google Scholar]
  • 12. Mitsui I, Kumazawa E, Hirota Y, Aonuma M, Sugimori M, Ohsuki S, Uoto K, Ejima A, Terasawa H, Sato K. A new water‐soluble camptothecin derivative, DX‐8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res 1995; 86: 776–82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Kumazawa E, Jimbo T, Ochi Y, Tohgo A. Potent and broad antitumor effects of DX‐8951f, a water‐soluble camptothecin derivative, against various human tumors xenografted in nude mice. Cancer Chemother Pharmacol 1998; 42: 210–20. [DOI] [PubMed] [Google Scholar]
  • 14. Kumazawa E, Tohgo A. Antitumour activity of DX—8951f: a new camptothecin derivative. Exp Opin Invest Drugs 1998; 7: 625–32. [DOI] [PubMed] [Google Scholar]
  • 15. Masubuchi N, Gohda R, Seki H, Hayashi K, Atsumi R, Inoue K. DE‐310, a novel macromolecular carrier system for the camptothecin analog DX‐8951f[III]: pharmacokinetic evaluation in normal and tumor‐bearing mice. Proc Am Assoc Cancer Res 2001; 42: 376. [Google Scholar]
  • 16. Sezaki H, Hashida M. Macromolecular‐drug conjugates in targeted cancer chemotherapy. CRC Crit Rev Ther Drug Carrier Systems 1985; 1: 1–38. [PubMed] [Google Scholar]
  • 17. Sezaki H, Takakura Y, Hashida M. Soluble macromolecular carriers for the delivery of antitumor drugs. Adv Drug Delivery Rev 1989; 3: 247–66. [Google Scholar]
  • 18. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor‐selective macromolecular drug targeting. Adv Enzyme Regul 2001; 41: 189–207. [DOI] [PubMed] [Google Scholar]
  • 19. Inoue K, Kumazawa E, Kuga H, Susaki H, Masubuchi N, Kajimura T. CM‐dextran‐polyalcohol‐camptothecin conjugate: DE‐310 with a novel carrier system and its preclinical data. Adv Exp Med Biol 2003; 519: 145–53. [DOI] [PubMed] [Google Scholar]
  • 20. Hart IR, Talmadge JE, Fidler IJ. Metastatic behavior of a murine reticulum cell sarcoma exhibiting organ‐specific growth. Cancer Res 1981; 41: 1281–7. [PubMed] [Google Scholar]
  • 21. Kohga S, Kinjo M, Tanaka K, Ogawa H, Ishihara M, Tanaka N. Effects of 5‐(2‐chlorobenzyl)‐4, 5, 6, 7‐tetrahydrothieno [3, 2—C] pyridine hydrochloride (ticlopidine), a platelet aggregation inhibitor, on blood‐borne metastasis. Cancer Res 1981; 41: 4710–4. [PubMed] [Google Scholar]
  • 22. Tanaka N, Ogawa H, Tanaka K, Kinjo M, Kohga S. Effects of tranexamic acid and urokinase on hematogenous metastases of Lewis lung carcinoma in mice. Invasion Metastasis 1981; 1: 149–57. [PubMed] [Google Scholar]
  • 23. Aaron RH, Elion GB, Colvin OM, Graham M, Keir S, Bigner DD, Friedman HS. Busulfan therapy of central nervous system xenografts in athymic mice. Cancer Chemother Pharmacol 1994; 35: 127–31. [DOI] [PubMed] [Google Scholar]
  • 24. Tanaka N, Ashida S, Tohgo A, Ogawa H. Platelet‐aggregating activities of metastasizing tumor cells. Invasion Metastasis 1982; 1: 289–98. [PubMed] [Google Scholar]
  • 25. Tohgo A, Tanaka N, Ahida S, Ogawa H. Platelet‐aggregating activities of metastasizing tumor cells. II. Variety of the aggregation mechanisms. Invasion Metastasis 1984; 4: 134–45. [PubMed] [Google Scholar]
  • 26. Fujita F, Fujita M, Taguchi T, Shimozuma K, Sakamoto Y, Kimoto Y, Hirai T. Multifactorial analysis of parameters influencing chemosensitivity of human cancer xenografts in nude mice. Int J Cancer 1989; 43: 637–44. [DOI] [PubMed] [Google Scholar]
  • 27. Rose WC. Evaluation of Madison 109 lung carcinoma as a model for screening antitumor drugs. Cancer Treat Rep 1981; 65: 299–312. [PubMed] [Google Scholar]
  • 28. Kumazawa E, Ochi Y, Tanaka N, Kajimura T, Inoue K. DE‐310, a novel macromolecular carrier system for the camptothecin analog DX‐8951f[I]: its antitumor activities in the murine Meth A solid tumor model. Proc Am Assoc Cancer Res 2001; 42: 139. [Google Scholar]
  • 29. Ochi Y, Kumazawa E, Shiose Y, Kuga H, Inoue K. DE‐310, a novel macromolecular carrier system for the camptothecin analog DX‐8951f[IV]: a possible drug release mechanism for antitumor activity. Proc Am Assoc Cancer Res 2003; 44: 395. [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES